Evidence map›Paper›PMID 41750289›Full record

ReviewBiomolecules2026

The Interleukin-7 Receptor Signaling Pathway and Its Perturbation in Immunodeficiency, Autoimmune Disease and Lymphoid Malignancy.

Alister C Ward

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alister C WardSchool of Medicine, Deakin University, Geelong, VIC 3216, Australia.ORCID 0000-0001-7945-7975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-cell signaling through a network of cytokine receptors is pivotal for normal immune development and function, with disruptions of these signaling pathways being implicated in a variety of immune cell diseases. Signaling via the interleukin-7 receptor (IL-7R) facilitates the development and homeostasis of various T-cell, B-cell and other immune-cell populations. This is reflected in the raft of mutants and variants of IL-7R components and downstream signaling molecules that have been identified in the context of immunodeficiencies, autoimmune disorders and lymphoid malignancies, but also through the use of pathway modulators as therapeutics. This review provides an overview of IL-7R biology, the role of mutations and variants affecting IL-7R signaling pathway components in the etiology of immune cell diseases and the specific therapies related to this pathway.

Indexed as

Autoimmune DiseasesImmunologic Deficiency SyndromesReceptors, Interleukin-7Signal TransductionAnimalsHumansReceptors, Interleukin-7autoimmunitycytokineIL-7immunodeficiencyJAKleukemiaSTAT

Identifiers

PMID41750289
PMCPMC12937949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.